Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

Stopped early · Phase 4

Conditions studied: Thrombosis, Coronary Artery Disease

In brief

Personalized treatment approaches and antiplatelet drug choice have been proposed to optimize safety of coronary stenting by reducing heart attacks and repeat interventions while simultaneously minimizing adverse bleeding events. This study compares the efficacy of two laboratory guided treatment algorithms to personalize antiplatelet medication choice after coronary stenting

Key facts

Study ID

NCT01612884

Run by

Indiana University

People needed

67

Starts

2011-08-01

Expected to finish

2017-03-01

Last updated by the study team

2018-04-26

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients admitted with acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction) and referred for coronary angiography.
• Current therapy with clopidogrel (at least 300mg loading dose, or 75mg po daily for >5 days)
• Age range 21-75 years.

You may not qualify if…

• Unable to give consent
• Age younger than 21 years, greater than 75 years
• History of stroke
• Body weight <60 kg
• Acute STEMI,
• Thrombocytopenia<100'000,
• requirement for chronic warfarin therapy

Where it is running

• Eskenazi Health — Indianapolis, Indiana, United States
• Indiana University Health Methodist Hospital — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.